skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes

Original Research

(2628) Views  (694) Full article downloads

Authors: Marc K Israel, Eva Istvan, Michelle A Baron

Published Date September 2008 Volume 2008:4(6) Pages 1167 - 1178
DOI: http://dx.doi.org/10.2147/VHRM.S2718

Marc K Israel1, Eva Istvan2, Michelle A Baron1,3

1Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA; 2Novartis AG, Basel, Switzerland; 3Sanofi-Aventis, Bridgewater, New Jersey, USA

Abstract: The increasing prevalence of type 2 diabetes provides impetus for both development of new drugs to improve glycemic control and for reconsideration of treatment strategies with existing agents. Combination therapy with complementary drug classes that act on different aspects of glycemic control has been a particularly effective strategy. This work reviews the published literature reporting efficacy and safety/tolerability of nateglinide, a rapid-onset insulinotropic agent with a predominant effect to reduce postprandial glucose, when combined with metformin, a first-line agent that suppresses hepatic glucose production and thereby reduces fasting plasma glucose. The nateglinide/metformin combination has consistently been found to be both efficacious and well tolerated, whether given as initial combination therapy in drug-naïve patients or when added to metformin monotherapy. Maximum efficacy (Δ glycosylated hemoglobin [HbA1c] = –1.4% to –1.9%, sustained for up to 2 years of treatment) was seen in studies of drug-naïve patients in whom pharmacotherapy was initiated with the combination of nateglinide and metformin, and modest reductions in HbA1c (Δ = –0.5% to –1.2%, sustained for up to 24 weeks) were found when nateglinide was added to ongoing metformin monotherapy.

Conclusion: The combination of nateglinide and metformin provides a sustained degree of glycemic control not achievable with either agent given as monotherapy.

Keywords: metformin, nateglinide, combination therapy, type 2 diabetes, postprandial hyperglycemia








Readers of this article also read:

A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes
A review of nateglinide in the management of patients with type 2 diabetes
Review of biphasic insulin aspart in the treatment of type 1 and 2 diabetes
Combination treatment in the management of type 2 diabetes: focus on vildagliptin and metformin as a single tablet
Prevalence of risk factors, coronary and systemic atherosclerosis in abdominal aortic aneurysm: Comparison with high cardiovascular risk population
Alpha-glucosidase inhibitors in the early treatment of type 2 diabetes
Refinement of rigid-body protein–protein docking using backbone and side-chain minimization with a coarse-grained model
ABO and rhesus blood group distribution in Kurds
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Detection of retinal changes in Parkinson's disease with spectral-domain optical coherence tomography
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University